In addition, in serial tumor biopsies in patients receiving BRAF ± MEK inhibitor therapy a comparable increase in CD8 + tumor-infiltrating lymphocytes (TILs) and other T cell subsets (e.g., CD3 + , FOXP3 +) is observed over time indicating that the observed T cell enrichment is not selective. This evidence concerns the gene CD8A and neoplasm.